Walgreens Tries To Counter Ongoing Sales Slide With Purchase Of 144-Store Chain Walgreens announces planned acquisition of Stephen L. LaFrance Holdings drugstores in tandem with reporting a large drop in June's same-store sales.
PDUFA V: Review Model Evaluators Will Observe All FDA-Sponsor Meetings Interim and final assessments will help determine which parts of the new, longer application review help FDA take more first-cycle actions.
FDA Oxycodone Enforcement Built On Difference Between "Same" And "Identical" Companies must stop manufacturing unapproved single-ingredient, immediate-release oxycodone products in oral dosage forms within 45 days; FDA rejects Lannett petition, saying it has not provided evidence its oxycodone is identical to a pre-1938 product.
Forest Gender Discrimination Suit Cites "Striking" Similarities With Other Firms Forest is the fourth pharmaceutical company to face a sales rep gender discrimination class action by Sanford Wittels & Heisler; complaint seeks $100 million in damage as well as changes in pay and promotion.
Alnylam CEO John Maraganore - An Interview With "The Pink Sheet" DAILY (Part 1 of 2) The RNAi-pioneering biotech is sitting in a different position than it was a year ago, about to take its lead candidate into pivotal studies and with a new partnership with Arrowhead and $87 million in proceeds from one of the largest follow-on public offerings in recent memory by a biotech firm.
e-Therapeutics Explores Network Pharmacology For Drug Discovery, Moves First Of Its Drugs Into Clinical Studies The U.K. company e-Therapeutics outlines its novel "network pharmacology" approach for discovery R&D, its product pipeline, and collaboration plans as it moves its first product, with potential in cancer, into Phase I studies.
“The Pink Sheet” DAILY - daily in-depth analysis of the key developments shaping the biopharma industry. For more information call 1-800-332-2181. To register for a free trial, click here – no credit card needed.
